Trending...
- Aug. 11 (8/11) Serves as Reminder for Illinois Residents to Always Contact 811 Before Digging
- SIGGRAPH 2022 Hybrid Conference Enjoys Notable Numbers with In-Person and Virtual Attendees
- Ironbeam becomes CME Group Clearing Member
NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for its lead investigational product, TCMCB07, allowing the company to proceed with initiating clinical studies. TCMCB07 is an investigational melanocortin‐4 antagonist peptide designed to treat cachexia in people that have cancer and other chronic diseases. Endevica Bio plans to initiate Phase 2 clinical studies in pancreatic cancer in 2Q 2023.
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
- Boom Boom Firearms Training LLC., Is Hosting Maryland Wear & Carry Permit (CCW) 16-Hour Courses For Eligible MD Residents & Non Residents
- Improvement, data science pros to convene in Atlanta Sept. 19-21
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2022 October Speak Up Women Conference and Last Call For Speakers
- IRI and Ajinomoto Foods Expand Partnership to Proactively Combat Supply Issues
- Mandarina Houses presents a comprehensive solution to your real estate needs
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
- GTCR Forms Portfolio Resources Group to Support Portfolio Company Growth
- Bundledocs launch new Cloud PDF Editor as part of their entry into North American market
- Monroe Capital Supports Clarion Capital Partners' Recapitalization of Premiere Digital Services
- Non-profit Responds to Post Covid Needs
- Walgreens Boots Alliance Sells 11 Million Shares of Option Care Health
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
Filed Under: Business
0 Comments
Latest on illi News
- Ansira Accelerates Growth Heading Into Second Half of 2022 Driven By Significant Client Wins, Product Enhancements, and Continued Industry Accolades
- Ironside Human Resources Ranks No.765 on the 2022 Inc. 5000 Annual List
- CareWell Health Medical Center Expands Leadership Team, Adds New COO
- Global Workplace Mental Health Provider CuraLinc Healthcare Debuts on the Inc. 5000 List
- BigTime Software Named to 2022 Inc. 5000 List of Fastest Growing Companies in America
- Tales of Wonder and Dread To Mark Anniversary With New Books
- Arizona Fireplaces Ranks No. 3277 on the 2022 Inc. 5000 Annual List
- Motherly Named to 2022 Inc. 5000 Annual List Among America's Fastest-Growing Private Companies
- HAMILTON BEACH BRANDS HOLDING COMPANY TO PARTICIPATE IN MIDWEST IDEAS INVESTOR CONFERENCE
- Summit Report Released: Keeping Schools Open in 2022 and Beyond
- The BGL Industrials Insider -- Industrial Distribution M&A Remains Active Amid Market Uncertainty
- Rock Guitarist Reveals Secrets Of Sweep Picking Technique
- Illinois American Water Announces 2022 Firefighter Grant Program
- InventHelp Inventors Develop Portable Cigar/Cigarette Holder (CHK-114)
- Bold New Book, If Only We Knew, Offers A Framework To Understand And Solve Today's Social Issues
- Living Waters Inc to Host the "2022 Mental Health Summit"
- Lincoln Private Market Index Experiences First Decline Since Q1 2020
- Wood Underwear® FW22 Introduces New Styles in Lounge
- Winston & Strawn Adds Corporate Partner Aaron Berlin in Chicago
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts